Should you buy Regeneron Pharmaceuticals stock now?
Yes, the technical signal for Regeneron Pharmaceuticals is currently BUY. Regeneron Pharmaceuticals trades at $764.75 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 29.213 with rising momentum (signal: 19.021); RSI is at 77.9 (overbought), suggesting the price may have risen too quickly; the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $833.54 points to 9.0% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Regeneron Pharmaceuticals stock?
The average analyst price target for Regeneron Pharmaceuticals is $833.54. The current price is $764.75, which gives an upside of 9.0%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $750.19 and $916.89.
Is Regeneron Pharmaceuticals a dividend stock?
Yes, Regeneron Pharmaceuticals is a dividend stock with a dividend yield of 0.48%. The latest dividend was $0.94 per share. The latest ex-dividend date (traded without the dividend) was 8/18/2026. The payout ratio is 8.2%, which is considered sustainable. The next dividend payment is scheduled for 8/31/2026.
When does Regeneron Pharmaceuticals pay a dividend in 2026?
Regeneron Pharmaceuticals pays its next dividend on 8/31/2026. The latest dividend was $0.94 per share with an ex-dividend date of 8/18/2026. The dividend yield is 0.48%. The payout ratio of 8.2% points to a sustainable dividend with room to grow.
What is the risk of Regeneron Pharmaceuticals stock?
Regeneron Pharmaceuticals is rated as a stock with moderately low risk. the annual standard deviation is 33.6%, which classifies the stock as moderately low risk. In addition, an RSI of 77.9 signals overbought (elevated risk of a pullback).
Is Regeneron Pharmaceuticals overvalued?
Regeneron Pharmaceuticals is considered fairly valued – the price is close to the analyst price target. Regeneron Pharmaceuticals has the following valuation ratios: a P/E ratio of 18.8 (moderately valued), a P/S ratio of 5.0, a P/B ratio of 2.5. The stock trades close to the analyst price target and is considered fairly valued.
Is Regeneron Pharmaceuticals overbought?
Yes, Regeneron Pharmaceuticals is overbought with an RSI of 77.9 (above 70). The technical indicators show: RSI is at 77.9 (above the 70 mark), which signals the price is overbought and may have risen too quickly. In addition, the price is 10.6% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Regeneron Pharmaceuticals earnings report?
The date of the next earnings report for Regeneron Pharmaceuticals has not been published yet. Check the company's investor calendar for updates.
Is Regeneron Pharmaceuticals shorted?
Yes, Regeneron Pharmaceuticals is shorted with 3.6% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Regeneron Pharmaceuticals stock?
No, insiders are not buying Regeneron Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 130,030 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 288,443,042 $ sold. Active sellers include RYAN ARTHUR F, Zoghbi Huda Y, Huda Y Zoghbi and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Regeneron Pharmaceuticals a good stock?
Based on our total score, Regeneron Pharmaceuticals is rated as a good stock with a total score of 73 out of 100. The stock scores above average on value, quality and momentum – it is among the top 27% in our database. The score is made up of Value: 63/100, Quality: 79/100, Momentum: 78/100. In addition: a dividend of 0.48%; technical signal: Buy. Whether Regeneron Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Regeneron Pharmaceuticals stock?
The outlook for Regeneron Pharmaceuticals based on current data: the average analyst price target is $833.54 (+9.0%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 18.8 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Regeneron Pharmaceuticals stock rising?
Regeneron Pharmaceuticals is rising right now. The technical indicators show: the price is 10.6% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Regeneron Pharmaceuticals go?
The average analyst price target for Regeneron Pharmaceuticals is $833.54, which corresponds to a potential gain of 9.0% from the current price of $764.75. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Regeneron Pharmaceuticals fall?
We lack enough history to give a specific floor for Regeneron Pharmaceuticals. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Regeneron Pharmaceuticals do?
Regeneron, eller regn.us, er et stort medicinalselskab, der opdager, udvikler og sælger medicin mod forskellige sygdomme globalt. De tjener primært penge på at kommercialisere deres egne lægemidler.
De er især kendt for øjenmedicinen Eylea, som behandler øjensygdomme som maku... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Regeneron Pharmaceuticals as an investment.
Did Regeneron Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Regeneron Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Regeneron Pharmaceuticals making money or losing money?
Yes, Regeneron Pharmaceuticals is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 27.9% — which is excellent. The operating margin (profit before interest and taxes) is 33.1%. At a P/E ratio of 18.8, you currently pay 18.8 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Regeneron Pharmaceuticals go bankrupt?
The bankruptcy risk of Regeneron Pharmaceuticals is rated as low. Altman Z2 (a model for assessing financial distress) is 9.11 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 29% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Regeneron Pharmaceuticals have a lot of debt?
No, Regeneron Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 29%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Regeneron Pharmaceuticals service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 129.1x, and the company has more cash than debt (net cash).
